Background Canine visceral hemangiosarcoma (HSA) is a highly aggressive cancer of endothelial origin that closely resembles human visceral angiosarcoma, both clinically and histopathologically. Currently there is an unmet need for new diagnostics and therapies for both forms of this disease. The goal of this study was to utilize ChRO-seq and immunohistochemistry (IHC) to identify gene and protein expression signatures that may be important drivers of HSA progression.
20%. This breed predisposition suggests an inherited component to HSA [11] . Genome wide association studies have been carried out to identify risk loci [12] [13] . SNP array analysis on genomic DNA from HSA Golden Retriever tumor samples identified a risk locus on chromosome 5 that was shared by ~ 20% of the cases. In another study, microarray analysis on genomic DNA revealed gained copy number aberrations on several genes such as PDGFRA, KDR and VEGFA. A recent whole exome sequencing study revealed somatic mutations in tumor suppressor genes, including TP53, and two genes (PIK3CA and PIK3R1) in the PI3K pathway. These mutations were not breed-specific but were present across many different breeds. Comparison of somatic copy number aberration profiles in human angiosarcoma and canine hemangiosarcoma identified recurrent copy number gains in KDR (31% in human, 22% in canine) and KIT (17% in both) [14] . These genome-wide association studies revealed that while specific genetic aberrations are associated with HSA in some populations, these alterations are not sufficient to explain the majority of HSA cases, thus further supporting the heterogeneity of HSA pathogenesis.
Transcriptome analysis has been previously performed on both HSA cell lines and tumor tissues to identify molecular features that define canine HSA. Gene expression profiling of HSA cell lines and non-malignant proliferating endothelial cells revealed that HSA cell lines appeared to overexpress genes associated with inflammation, angiogenesis, adhesion, invasion, metabolism, cell cycle progression, and patterning [15] . Microarray and RNA-seq analysis of visceral HSA tumors identified three distinct molecular subtypes; angiogenesis, inflammation and lipogenesis. These molecular subtypes did not appear to be associated with a specific breed or tumor morphologic subtype [16] .
A variety of analytic tools exist for assaying the transcriptome and molecular alterations in tissue. One of these tools, ChRO-seq, uses RNA polymerase activity to measure transcription and, as such, provides for a highly-sensitive, base-pair level readout of gene expression [17] [18] . Given the lack of clarity regarding the molecular underpinnings of HSA, the major goal of this study was to utilize chromatin run-on sequencing (ChRO-seq) to document changes in gene expression between normal splenic tissue and HSA tumor tissue. Our results show that the majority of genes that are upregulated in HSA tumor tissue appear to be associated with extracellular matrix (ECM) remodeling. Additionally, we further characterize two ECM-associated molecules that we found to be highly overexpressed in HSA tumor tissue, podoplanin (PDPN) and laminin alpha 4 (LAMA4), and show by immunohistochemistry (IHC) that the expression of these two cancer-associated factors appears to be primarily limited to HSA tumor cells.
Materials And Methods

Samples
Canine tissue samples were obtained from the Canine Comparative Oncology & Genomics Consortium and Cornell University Hospital for Animals. Pathology was independently confirmed and patient demographics are described in the supplemental material (Table   S1 ). ChRO-seq libraries were made from splenic hemangiosarcoma (n = 20) and normal splenic tissues from HSA dogs (n = 4).
Precision Run On sequencing
Chromatin was extracted from each tissue sample and chromatin run-on was performed as Briefly, slides were boiled for 40 minutes in 0.01 M sodium citrate to retrieve antigens.
Slides were cooled and washed in running tap water for 20 minutes, then incubated for 15 minutes in 3% hydrogen peroxide to quench endogenous peroxidases. Slides were blocked in 2.5% normal goat serum for 30 minutes at room temperature. Primary antibodies were diluted in 1% BSA/TBST, and incubated overnight at 4C. Slides were washed three times with TBS-T, then incubated with a secondary antibody for 1 hour at room temperature (Goat anti-mouse-HRP, Vector laboratories, Inc., Burlingame, CA; #MP7452 or Goat antirabbit-HRP, Vector laboratories, Inc., #MP7451). ImmPACT NovaRED peroxidase substrate (Vector laboratories, Inc., SK-4805) with hematoxylin counterstain was used for signal detection. Slides were dehydrated through 80, 95 and 100% EtOH to Xylene and coverslipped.
RT-PCR
Snap frozen tissue was pulverized in tissue crasher and total RNA was extracted with Trizol reagent. 1∝ g of RNA was reverse-transcribed to cDNA using Applied Biosystems High-capacity cDNA reverse transcription kit following the manufacture's protocol. All cDNA reactions were diluted 5-fold with water prior to use in PCR. 1∝ l of diluted cDNA was used for PCR using Go-Taq master mix (Promega Corporation) with canine specific primers (supplement table 2), and amplified products were analyzed on agarose gel electrophoresis.
Discussion
In this study, we first utilized precision-run-on sequencing to identify RNA polymerase activity in hemangiosarcoma tumor tissue and normal splenic tissue. Analysis of the correlation matrix for our ChRO-seq dataset finds that 14 of the HSA tumor samples clustered together, while 3 of the HSA samples appeared to be more similar to normal splenic tissue ( Fig. 1 ). While speculative, it is possible that these 3 samples represent a different subtype of HSA and, as such, displayed a gene expression profile that is more similar to normal tissue. Alternatively, it is also possible that, these 3 presumptive HSA tissues were actually tumor-adjacent normal tissue or a mix of normal and tumor tissue.
While grading of canine hemangiosarcoma is not often utilized due to the aggressive nature of the neoplasm, a grading scheme does exist and differences in gene expression may correlate to progression and eventual outcome [26] .
Previous HSA transcriptomic profiling studies have implicated a number of signaling pathways in HSA pathogenesis. Tamburini et al, for example, found HSA cells exhibited a several different distinct gene expression profiles, including signatures for angiogenesis and inflammation [15] . In another study, Gorden et al performed microarray and RNA-seq analyses on visceral HSA tumor tissues and identified three distinct tumor subtypes that were associated with either angiogenesis, inflammation, and adipogenesis. Our study differs from these previous reports in that we found ECM remodeling to be the most significantly upregulated biological process in HSA tumor tissue. Precisely what accounts for the discrepancy between our study and previous studies is not clear.
Regarding the specific types of ECM factors that were upregulated in our dataset ( [36, 37] along with ADAMTS14, ADAMTS4, ADAM12 and TLL1 which process procollagen to collagen by cleaving N-propeptide and C-propeptide [38, 39] . Lastly, two molecules directly involved in ECM turnover, tissue inhibitor of metalloproteinase 1 (TIMP1) and matrix metalloproteinase 14 (MMP14), were also found in this dataset [40, 41] [42] . The extent to which ECM genes were upregulated in HSA tumors in our study is highlighted by our GO analysis which found that 9 of the top 10 biological process categories were ECM-related (Fig. 2) . Interestingly, 5 of these 9 categories related to collagen function. We more directly tested for the abundance of collagen fibers in the tumor samples using Masson's trichrome stain and found extensive collagen deposition throughout the tumor tissue ( Fig. 3) . Collagen deposition was observed both in the more solid areas of the tumor and, in particular, in the tumor regions filled with malformed vascular channels. In these vascular regions, neoplastic endothelial cells are often found to encircle the collagen bundles forming "gumball"-shaped structures that look like inverted blood vessels. While stromal fibroblasts are presumably primarily responsible for the synthesis of these collagen fibers, it is also possible that the tumor cells may also be partly responsible for synthesis of these collagen fibers.
In addition to collagen, we also found that PDPN and LAMA4 were highly overexpressed in HSA tumor tissue when compared to normal tissue. These molecules were of particular interest to us given their close association with cancer progression in other types of cancer. Podoplanin is a mucin-type protein that contains an extracellular region, transmembrane domain, and intracellular tail. It is widely known as a marker for lymphatic endothelial cells and also to play a critical role in heart and lung development and in development of the lymphatic endothelial system [43] [44] [45] . PDPN appears to play several roles in cancer progression. A number of studies have shown that PDPN expression in cancer cells promotes tumor cell proliferation and invasion [46] [47] [48] . In addition to cellintrinsic effects, PDPN is also believed to promote tumor metastasis by interacting with its receptor, CLEC2, on the platelets. This interaction then promotes the coating of tumor cells by platelets, thereby protecting tumor cells from the immune system [49] . In addition to its role in human cancers, PDPN is also overexpressed in canine squamous cell carcinomas and melanomas [50] and PDPN mAbs were recently found to have potent antitumor activity in mouse xenograft models of canine melanoma [51] . Interestingly, overexpression of PDPN in mice leads to disseminated intravascular coagulation [52] , a condition that is strikingly similar to that seen in many dogs with HSA [53]. Our ChRO-seq data demonstrated that PDPN expression varies significantly between HSA samples (Fig. 1,   4 ). IHC analysis found that PDPN was robustly expressed in transformed endothelial cells in certain HSA tumor samples. However, similar to our ChRO-seq finding, we did find that PDPN appears to only be expressed in a subset of HSA tumors. In future studies, we plan to test whether PDPN expression in HSA tumors correlates with disease severity.
Laminins form large heterotrimeric αβγ protein complexes and are a prominent component of basement membranes. LAMA4 is distinct from other laminin isoforms in that it lacks a polymerization domain with the loss of this domain potentially facilitating tumor cell migration [54] . Interestingly, LAMA4 was recently described as an "oncolaminin" due to its strong association with cancer cell migration and tumor progression in a range of cancers [55] . These links to cancer include recent studies which found that LAMA4 and MCAM (melanoma cell adhesion molecule) are highly enriched in tumor blood vessels in renal cell carcinoma and colorectal carcinoma. Additionally another study found that expression of these molecules is enhanced in locally invasive and metastatic clear cell renal cell carcinoma [56] . Further, antisense oligonucleotides against laminin-8 (LAMA4 and LAMB1) were found to block the invasion of glioma cells and neovascularization in vitro [ 57] .
Taken together, these published studies indicate that LAMA4 plays a key role for vascular development, tumor progression and metastasis. In our study, deseq2 analysis found that LAMA4 is highly transcribed in HSA tumor tissue. This observation was supported by PCR analysis of mRNA isolated from HSA tumor tissue ( Fig. 4) . Additionally, our IHC analysis found that LAMA4 protein expression appears to be primarily limited to malignant endothelial cells (Fig. 5) . Given the previously defined roles for LAMA4 in cancer progression and tumor metastasis, our findings raise the possibility that LAMA4 is an important mediator of canine HSA pathobiology.
Conclusions
Outcomes from our studies found that the majority of upregulated genes in HSA tumor tissue appear to be associated with ECM remodeling. This finding was supported by IHC analysis which found a robust collagen network throughout HSA tumor tissue. Additionally, we further characterized two ECM-associated factors, PDPN and LAMA4, found that their expression was largely limited to tumor cells in HSA tissue. Both of these molecules have been previously identified as potential biomarkers in other types of cancer. Given the recent previous preclinical mouse studies showing that anti-canine PDPN antibodies can block the growth of melanomas, our findings raise the possibility that similar types of therapies may have utility for treating canine HSA.
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fastq files will be submitted to GEO upon the manuscript accepted. seen to surround what appears to be collagen bundles. PDPN was also detected in tumor cells from the more avascular regions of the tumor (data not shown). c=low magnification d= high magnification. Scale bar represents 50 m.
Figure 6
Immunohistochemical localization of LAMA4 protein in normal and HSA tumor 30 tissue. (a) LAMA4 detection was low to absent in normal splenic tissue. (b) LAMA4 detection appears weak in the cytoplasm of endothelial cells of blood vessels that are adjacent to tumor masses. (c and d) LAMA4 staining is strong in the cytoplasm of tumor cells within the tumor's vascular regions. In these regions the LAMA4-positive tumor cells were seen to surround what appears to be collagen bundles. LAMA4 was also detected in tumor cells from the more avascular regions of the tumor (data not shown). c=low magnification d= high magnification. Scale bar represents 50 m.
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